AI-powered imaging specialist Brainomix has completed an $18 million Series C investment round to fuel its expansion in the United States and advance its technology into new therapeutic areas. The funding round was co-led by existing investors Parkwalk Advisors and the Boehringer Ingelheim Venture Fund, with participation from new investors Hostplus via the IP Group Hostplus Innovation Fund and LifeSci Capital.
Brainomix develops AI-powered software platforms that enable precision medicine for better treatment decisions in stroke and lung fibrosis. The company's flagship products include Brainomix 360 e-Lung, which predicts the progression of lung fibrosis, and Brainomix 360 Stroke, which automates imaging biomarkers to enhance diagnosis and treatment decisions for stroke patients.
The company plans to use the newly secured funds to accelerate its commercial expansion into the U.S. market, where it has already obtained ten FDA clearances for its technologies. Additionally, the investment will support Brainomix's strategic initiatives to advance its portfolio of AI-powered solutions into new clinical areas.
Michalis Papadakis, CEO and cofounder at Brainomix, expressed gratitude for the investment support: "We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognize the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients."
He added, "We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies."
The Series C funding builds on Brainomix's growing momentum in the healthcare AI space. In February, the company announced a strategic partnership with Medtronic Neurovascular aimed at enhancing stroke care for patients across Western Europe by integrating AI solutions into clinical practice, with the goal of expanding access to treatments and improving patient outcomes.
In 2023, Brainomix received £400,000 ($420,418) alongside remote robotic surgical company Nanoflex Robotics to develop an AI-assisted magnetic navigation system for stroke-related robotic surgical tools.
Prior to the current funding round, Brainomix closed a Series B round in 2021, securing approximately £16 million ($20.7 million) in investment led by Boehringer Ingelheim Venture Fund and Oxford University Innovation Fund, with participation from Tencent Holdings.
Click here for the original news story.